The stock has a 36-month beta value of 1.83. Opinions on the stock are mixed, with 2 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CVKD is 0.44M, and at present, short sellers hold a 4.10% of that float. On October 18, 2024, the average trading volume of CVKD was 37.31K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
CVKD) stock’s latest price update
The stock price of Cadrenal Therapeutics Inc (NASDAQ: CVKD) has jumped by 6.19 compared to previous close of 15.35. Despite this, the company has seen a gain of 44.63% in its stock price over the last five trading days. prnewswire.com reported 2024-09-23 that PONTE VEDRA, Fla., Sept. 23, 2024 /PRNewswire/ — Cadrenal Therapeutics, Inc., (Nasdaq: CVKD), a late-stage biopharmaceutical company developing tecarfarin, a new vitamin K antagonist (VKA) designed to be a superior and safer chronic anticoagulant for warfarin-dependent patients with implanted cardiac devices or rare cardiovascular conditions, announced today it will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2024 Investor Conference, taking place virtually on Tuesday, October 1, 2024.
CVKD’s Market Performance
Cadrenal Therapeutics Inc (CVKD) has experienced a 44.63% rise in stock performance for the past week, with a 36.06% rise in the past month, and a 152.71% rise in the past quarter. The volatility ratio for the week is 13.65%, and the volatility levels for the past 30 days are at 11.26% for CVKD. The simple moving average for the past 20 days is 25.22% for CVKD’s stock, with a 73.01% simple moving average for the past 200 days.
Analysts’ Opinion of CVKD
Many brokerage firms have already submitted their reports for CVKD stocks, with Noble Capital Markets repeating the rating for CVKD by listing it as a “Outperform.” The predicted price for CVKD in the upcoming period, according to Noble Capital Markets is $4 based on the research report published on December 18, 2023 of the previous year 2023.
CVKD Trading at 61.79% from the 50-Day Moving Average
After a stumble in the market that brought CVKD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -49.92% of loss for the given period.
Volatility was left at 11.26%, however, over the last 30 days, the volatility rate increased by 13.65%, as shares surge +45.41% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +162.67% upper at present.
During the last 5 trading sessions, CVKD rose by +44.63%, which changed the moving average for the period of 200-days by +63.70% in comparison to the 20-day moving average, which settled at $13.02. In addition, Cadrenal Therapeutics Inc saw 46.87% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for CVKD
Current profitability levels for the company are sitting at:
- -2394.75 for the present operating margin
- 0.18 for the gross margin
The net margin for Cadrenal Therapeutics Inc stands at -2253.17. The total capital return value is set at -1.66. Equity return is now at value -174.01, with -138.35 for asset returns.
Based on Cadrenal Therapeutics Inc (CVKD), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -532.95. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is 488.59.
Currently, EBITDA for the company is -7.63 million with net debt to EBITDA at 0.77. When we switch over and look at the enterprise to sales, we see a ratio of 4468.02. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.60.
Conclusion
To sum up, Cadrenal Therapeutics Inc (CVKD) has seen a better performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
